Carl Zeiss Meditec AG

Report azionario XTRA:AFX

Capitalizzazione di mercato: €4.0b

Carl Zeiss Meditec Crescita futura

Criteri Future verificati 3/6

Carl Zeiss Meditec prevede che gli utili e i ricavi cresceranno rispettivamente di 19.8% e 6.3% all'anno. Si prevede che l'EPS crescerà di 19.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 11.3% in 3 anni.

Informazioni chiave

19.8%

Tasso di crescita degli utili

19.42%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili12.8%
Tasso di crescita dei ricavi6.3%
Rendimento futuro del capitale proprio11.28%
Copertura analitica

Good

Ultimo aggiornamento10 Sep 2025

Aggiornamenti recenti sulla crescita futura

Carl Zeiss Meditec AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 10
Carl Zeiss Meditec AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

Carl Zeiss Meditec AG's (ETR:AFX) Share Price Matching Investor Opinion

Aug 29
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Matching Investor Opinion

Carl Zeiss Meditec AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 10
Carl Zeiss Meditec AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital

Jul 01
Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital

Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems

May 19
Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems

Is It Time To Consider Buying Carl Zeiss Meditec AG (ETR:AFX)?

May 16
Is It Time To Consider Buying Carl Zeiss Meditec AG (ETR:AFX)?

Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 39%?

Apr 28
Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 39%?

Carl Zeiss Meditec (ETR:AFX) Will Pay A Smaller Dividend Than Last Year

Mar 23
Carl Zeiss Meditec (ETR:AFX) Will Pay A Smaller Dividend Than Last Year

Shareholders Will Probably Be Cautious Of Increasing Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation At The Moment

Mar 20
Shareholders Will Probably Be Cautious Of Increasing Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation At The Moment

After Leaping 25% Carl Zeiss Meditec AG (ETR:AFX) Shares Are Not Flying Under The Radar

Mar 15
After Leaping 25% Carl Zeiss Meditec AG (ETR:AFX) Shares Are Not Flying Under The Radar

These 4 Measures Indicate That Carl Zeiss Meditec (ETR:AFX) Is Using Debt Extensively

Mar 03
These 4 Measures Indicate That Carl Zeiss Meditec (ETR:AFX) Is Using Debt Extensively

Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively

Feb 10
Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively

More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%

Jan 10
More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%

Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?

Dec 28
Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?
User avatar

AI-Powered Innovations Like KINEVO 900 S And VISUMAX 800 Set To Drive Revenue Growth

New product pipeline and integration of DORC expected to drive revenue and enhance net margins with innovative AI medical solutions.

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Dec 04
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk

Nov 19
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk

Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital

Sep 19
Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital

Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Sep 06
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?

Aug 23
Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?

At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?

Aug 09
At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?

Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Jul 11
Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled

Jun 10
Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled

Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing

May 26
Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing

Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 11
Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

May 09
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?

Mar 24
Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?

Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Mar 11
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement

Feb 12
Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Jan 29
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?

Dec 08
What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?

Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital

Nov 08
Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital

Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price

Oct 24
Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price

Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?

Sep 24
Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?

Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?

Sep 08
Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Jul 24
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)

Jun 19
We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)

Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?

Jun 06
Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?

Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?

May 22
Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?

Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price

Apr 19
Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price

Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet

Feb 26
Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet

Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 10
Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year

Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching

Jan 28
Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching

Previsioni di crescita degli utili e dei ricavi

XTRA:AFX - Stime future degli analisti e dati finanziari passati (EUR Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/20282,673284325N/A4
9/30/20272,470218233N/A14
9/30/20262,301176210N/A15
9/30/20252,197139133N/A15
6/30/20252,180150N/AN/AN/A
3/31/20252,16915683196N/A
12/31/20242,082157N/AN/AN/A
9/30/20242,06617995247N/A
6/30/20242,066203N/AN/AN/A
3/31/20242,062261122263N/A
12/31/20232,094277N/AN/AN/A
9/30/20232,089290137251N/A
6/30/20232,080308N/AN/AN/A
3/31/20232,02227863162N/A
12/31/20221,963307N/AN/AN/A
9/30/20221,903294106188N/A
6/30/20221,781245N/AN/AN/A
3/31/20221,735264207285N/A
12/31/20211,688228N/AN/AN/A
9/30/20211,647236297363N/A
6/30/20211,566235N/AN/AN/A
3/31/20211,388159240290N/A
12/31/20201,335130N/AN/AN/A
9/30/20201,335122134179N/A
6/30/20201,400120N/AN/AN/A
3/31/20201,507166132171N/A
12/31/20191,505170N/AN/AN/A
9/30/20191,459160173220N/A
6/30/20191,382153N/AN/AN/A
3/31/20191,334129N/A242N/A
12/31/20181,310127N/AN/AN/A
9/30/20181,281126N/A187N/A
6/30/20181,251124N/AN/AN/A
3/31/20181,216129N/A56N/A
12/31/20171,205132N/AN/AN/A
9/30/20171,190134N/A38N/A
6/30/20171,154123N/AN/AN/A
3/31/20171,135112N/A85N/A
12/31/20161,106113N/AN/AN/A
9/30/20161,08898N/A112N/A
6/30/20161,09078N/A132N/A
3/31/20161,08380N/A96N/A
12/31/20151,06261N/A73N/A
9/30/20151,04062N/A57N/A
6/30/201598470N/A34N/A
3/31/201594666N/A44N/A
12/31/201493873N/A60N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di AFX ( 19.8% all'anno) è superiore al tasso di risparmio ( 1.4% ).

Guadagni vs Mercato: Si prevede che gli utili di AFX ( 19.8% all'anno) cresceranno più rapidamente del mercato German ( 16.6% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di AFX cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di AFX ( 6.3% all'anno) crescerà più rapidamente del mercato German ( 6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AFX ( 6.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di AFX sarà basso tra 3 anni ( 11.3 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/10/06 18:13
Prezzo dell'azione a fine giornata2025/10/06 00:00
Utili2025/06/30
Utili annuali2024/09/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Carl Zeiss Meditec AG è coperta da 34 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jonathon UnwinBarclays
Scott BardoBerenberg
Samuel EnglandBerenberg